Literature DB >> 32717165

Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience.

Kevin B Ginsburg1, Michael L Cher1, James E Montie2.   

Abstract

Mesh:

Year:  2020        PMID: 32717165     DOI: 10.1097/JU.0000000000001308

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  4 in total

1.  National consensus quality indicators to assess quality of care for active surveillance in low-risk prostate cancer: An evidence-informed, modified Delphi survey of Canadian urologists/radiation oncologists.

Authors:  Narhari Timilshina; Antonio Finelli; George Tomlinson; Anna Gagliardi; Beate Sander; Shabbir M H Alibhai
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 1.862

2.  Five-year follow-up study of a population-based prospective cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS): study protocol.

Authors:  Jinping Xu; Michael Goodman; James Janisse; Michael L Cher; Cathryn Hufford Bock
Journal:  BMJ Open       Date:  2022-02-21       Impact factor: 2.692

3.  Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.

Authors:  Randy A Vince; Ralph Jiang; Daniel E Spratt; Todd M Morgan; Ji Qi; Jeffrey J Tosoian; Rebecca Takele; Felix Y Feng; Susan Linsell; Anna Johnson; Sughand Shetty; Patrick Hurley; David C Miller; Arvin George; Khurshid Ghani; Fionna Sun; Mariana Seymore; Robert T Dess; William C Jackson; Matthew Schipper
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-07-20       Impact factor: 5.554

4.  Patient Preferences and Treatment Decisions for Prostate Cancer: Results From A Statewide Urological Quality Improvement Collaborative.

Authors:  Roshan Paudel; Stephanie Ferrante; Ji Qi; Rodney L Dunn; Donna L Berry; Alice Semerjian; Christopher M Brede; Arvin K George; Brian R Lane; Kevin B Ginsburg; James E Montie; Giulia I Lane
Journal:  Urology       Date:  2021-04-29       Impact factor: 2.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.